AC Immune (ACIU) has disclosed that its partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ) has temporarily paused enrollments in a mid-stage trial for their jointly developed Alzheimer’s candidate ACI-35.030/JNJ-2056.
The companies are advancing ACI-35.030/JNJ-2056 as part of a licensing and commercialization deal they signed in 2015, allowing the Swiss biotech to initially receive as much as $509M from the New Jersey-based pharma giant.
The Phase 2b study ReTain was designed to evaluate the effect of the anti-phospho-Tau vaccine candidate on the cognitive decline of those with preclinical Alzheimer’s disease.
“While the Phase 2b Retain trial continues, enrollment has been temporarily paused while Janssen evaluates aspects of the trial (including recruitment),” AC Immune (ACIU) said in an SEC filing on Tuesday.
However, the company ruled out any impact on its liquidity position from J&J’s (JNJ) decision and noted that its existing capital resources will be adequate to fund its operating requirements into Q3 2027.